AstraZeneca PLC - Change in ADS ratio AstraZeneca PLC (the "Company") today announces an intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme. The current ratio is one (1) American Depositary Share ("ADS") per one (1) Ordinary Share. The new ratio will be two (2) ADSs per one (1) Ordinary Share. The expected effective date for the ratio change is 27 July 2015. There will be no change to the underlying Ordinary Shares. ADS holders at the close of business New York time on the record date, 22 July 2015, will receive a distribution of one additional ADS for every ADS held. The new ADSs are expected to be distributed on 24 July 2015. No action is required by ADS holders to effect this change. Contact details for Citibank, N.A., the Company's ADR depositary, can be found below. A C N Kemp Company Secretary 26 June 2015 CONTACT Citibank Shareholder Services PO Box 43077 Tel (toll free in the US): +1-888-697-8018 Providence Tel (outside the US): +1-781-575-4555 RI 02940-3077 US Media Enquiries Esra Erkal-Paler +44 20 7604 8030 (UK/Global) Jacob Lund +46 8 553 260 20 (Sweden) Michele Meixell + 1 302 885 6351 (US) Investor Enquiries UK Thomas +44 20 7604 8199 mob: +44 7818 524185 Kudsk Larsen Eugenia Respiratory, Inflammation +44 20 7604 8233 mob: +44 7884 735627 Litz and Autoimmunity Nick Cardiovascular andMetabolic +44 1763 263 994 mob: +44 7717 618834 Stone Disease Karl Hård Oncology +44 20 7604 8123 mob: +44 7789 654364 Craig Infection, Neuroscience +44 20 7604 8591 mob: +44 7881 615764 Marks and Gastrointestinal Disease Christer +44 20 7604 8126 mob: +44 7827 836825 Gruvris US Dial / 301-398-3251 866-381-7277 Toll-Free
Change in ADS ratio
| Source: AstraZeneca PLC